伊匹木单抗10 mg/kg对比3 mg/kg治疗不可切除或转移性黑色素瘤:一项随机、双盲、多中心、3期试验
这项在21国87中心开展的随机双盲3期试验纳入727例不可切除III/IV期黑色素瘤患者,比较伊匹木单抗10 mg/kg与3 mg/kg。10 mg/kg组中位总生存15.7个月,3 mg/kg组11.5个月(HR 0.84,95%CI 0.70-0.99;p=0.04),但3-4级治疗相关不良事件和严重不良事件更多。
要点
- 10 mg/kg组中位总生存15.7个月,优于3 mg/kg组的11.5个月(HR 0.84;p=0.04)。
- 10 mg/kg组3-4级腹泻10%、结肠炎5%、ALT升高3%、垂体炎3%,均高于3 mg/kg组。
- 10 mg/kg组治疗相关严重不良事件37%,3 mg/kg组18%;治疗相关死亡分别为4例(1%)和2例(<1%)。
核心结论
- 在晚期黑色素瘤患者中,伊匹木单抗10 mg/kg较3 mg/kg显著延长总生存,但治疗相关不良事件增加。
- 作者认为,尽管自研究启动以来晚期黑色素瘤治疗格局已变化,伊匹木单抗在医疗需求未满足的难治患者中的临床应用可能值得进一步评估。
研究设计与样本
- 随机、双盲、多中心3期试验,在21个国家87个中心开展。
- 纳入未经治疗或既往治疗过的不可切除III期或IV期黑色素瘤患者,且既往未接受BRAF抑制剂或免疫检查点抑制剂治疗。
- 按1:1随机分配至伊匹木单抗10 mg/kg或3 mg/kg,静脉输注90分钟,每3周一次,共4剂。
- 按转移分期、既往转移性黑色素瘤治疗和ECOG体能状态分层;主要终点为意向治疗人群的总生存。
- 共入组727例:10 mg/kg组365例(364例接受治疗),3 mg/kg组362例(全部接受治疗)。
主要发现
- 10 mg/kg组中位随访14.5个月(IQR 4.6-42.3),3 mg/kg组11.2个月(IQR 4.9-29.4)。
- 10 mg/kg组中位总生存15.7个月(95%CI 11.6-17.8),3 mg/kg组11.5个月(95%CI 9.9-13.3),HR 0.84(95%CI 0.70-0.99;p=0.04)。
- 3-4级治疗相关不良事件:腹泻10 mg/kg组37例(10%,364例中)vs 3 mg/kg组21例(6%,362例中);结肠炎19例(5%)vs 9例(2%);丙氨酸氨基转移酶升高12例(3%)vs 2例(1%);垂体炎10例(3%)vs 7例(2%)。
- 治疗相关严重不良事件:10 mg/kg组133例(37%)vs 3 mg/kg组66例(18%)。
- 治疗相关不良事件死亡:10 mg/kg组4例(1%)vs 3 mg/kg组2例(<1%)。
临床怎么用
- 作者认为,伊匹木单抗在医疗需求未满足的难治患者中的临床应用可能值得进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189. FINDINGS: Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6-42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9-29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6-17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9-13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70-0·99; p=0·04). The most common grade 3-4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two (<1%) patients died from treatment-related adverse events. INTERPRETATION: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment. FUNDING: Bristol-Myers Squibb.
引用
- Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017. PMID: 28359784. doi:10.1016/S1470-2045(17)30231-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。